



## Intercell AG: Changes to the Supervisory Board

**Vienna (Austria), December 15, 2006** – Intercell AG (VSE, "ICLL") announced today the following realignment in its Supervisory Board:

**Hans Küpper**, who represented the private equity firm Global Life Science Ventures on Intercell's Supervisory Board, resigns from his position resigned with effect of today.

The company would like to thank Hans Küpper for his good cooperation and long-term commitment to the company.

With this resignation, all venture capital firms have now left Intercell's Supervisory Board. The Supervisory Board now includes the following members: Michel Gréco (Chairman), Ernst-Günter Afting (Vice-chairman), Staph Bakali, David Ebsworth, James Sulat and Hans Wigzell.

### About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information please visit: [www.intercell.com](http://www.intercell.com)

For more information, please visit: [www.intercell.com](http://www.intercell.com)

### Contact Intercell AG:

Katharina Wieser  
Head of Corporate Communications  
Campus Vienna Biocenter 2, A-1030 Vienna  
P: +43-1-20620-303 Mail to: [kwieser@intercell.com](mailto:kwieser@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

